Company Participants Conference Call Participants Operator I would now like to hand the conference over to your speaker today, Stephen Kilmer, Investor Relations. Please go ahead. Thank you. Good afternoon everyone. Let me start by pointing out that this conference call will include forward-looking statements within the meaning of applicable securities laws of the United States and Canada. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, perform ...

Exhibit 99.2 PROFOUND MEDICAL CORP. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS MARCH 31, 2023 PRESENTED IN US DOLLARS (000s) Profound Medical Corp. Interim Condensed Consolidated Balance Sheets In USD (000s) (Unaudited) | | March 31, | December 31, | | --- | --- | --- | | | 2023 | 2022 | | | $ | $ | | Assets | | | | Current assets | | | | Cash | 42,984 | 46,517 | | Trade and other receivables (note 3) | 6,995 | 6,344 | | Inventory (note 4) | 8,125 | 7,941 | | Prepaid expenses and deposits | 861 | 1 ...

Profound Medical Corp. (NASDAQ:PROF) Q4 2022 Earnings Conference Call March 7, 2023 4:30 PM ET Stephen Kilmer – Investor Relations Arun Menawat – Chief Executive Officer and Chairman Rashed Dewan – Chief Financial Officer Michael Sarcone – Jefferies Rahul Sarugaser – Raymond James Ben Haynor – Alliance Frank Takkinen – Lake Street Brian Gagnon – Gagnon Securities Scott McAuley – Paradigm Capital Good day and thank you for standing by. Welcome to the Profound Medical Fourth Quarter and Full Year 2022 Financi ...

NASDAQ: PROF TSX: PRN Certain statements in this presentation may contain certain information that is "forward-looking information" or "forward-looking statements" within the meaning of applicable securities laws with respect to Profound Medical Corp. ("Profound" or the "Company"). Such statements include all statements other than statements of historical fact contained in this presentation, such as statements that relate to the Company's current expectations and views of future events. Often, but not alway ...

EXHIBIT 99.1 G&A expenses for the 2022 fourth quarter decreased by 35% to approximately $2.1 million, compared with approximately $3.2 million in the same period in 2021, due to lower salaries and benefits, consulting fees, share based compensation, rent, software, insurance and other expenses. Fourth quarter 2022 S&D expenses decreased by 27% to approximately $1.7 million, compared with $2.3 million in the fourth quarter of 2021. This was driven by lower salaries and benefits, consulting fees and share bas ...

Profound Medical Corp. (NASDAQ:PROF) Q3 2022 Results Conference Call November 3, 2022 4:30 PM ET Company Participants Stephen Kilmer - IR Dr. Arun Menawat - CEO Rashed Dewan - CFO Conference Call Participants Michael Sarcone - Jefferies Rahul Sarugaser - Raymond James Brian Gagnon - Gagnon Securities Operator Good day, and thank you for standing by. Welcome to the Profound Medical Incorporated Third Quarter 2022 Conference Call. [Operator Instructions] Please be advised that today's conference is being reco ...

Profound Medical Corp. (NASDAQ:PROF) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants Stephen Kilmer - IR Dr. Arun Menawat - CEO Rashed Dewan - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Zach Weiner - Jefferies Rahul Sarugaser - Raymond James Operator Welcome to the Profound Medical Second Quarter 2022 Financial Results Conference Call. My name is Darryl, and IÂ'll be your operator for todayÂ's call. [Operator Instructions] I will now turn the ...

Profound Medical Corp. (NASDAQ:PROF) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Dr. Arun Menawat – Chief Executive Officer and Chairman of the Board Rashed Dewan – Chief Financial Officer Stephen Kilmer – Investor Relations Conference Call Participants Rahul Sarugaser – Raymond James Frank Takkinen – Lake Street Capital Markets Josh Jeggings – Cowen and Company Scott McAuley – Paradigm Capital Brian Gagnon – Gagnon Securities Operator Good day, and thank you for standing by ...

Profound Medical Corp. (NASDAQ:PROF) Q4 2021 Results Conference Call March 3, 2022 4:30 PM ET Company Participants Stephen Kilmer - IR Dr. Arun Menawat - CEO Rashed Dewan - CFO Conference Call Participants Rahul Sarugaser - Raymond James Josh Jennings - Cowen Frank Takkinen - Lake Street Capital Brian Gagnon - Gagnon Securities Ben Haynor - Alliance Global Partners Operator Hello. Thank you for standing by. Welcome to the Profound Medical Q4 and Full Year 2021 Financial Results Conference Call. At this time ...

EXHIBIT 99.1 Profound Medical Announces Fourth Quarter and Full Year 2021 Financial Results TORONTO, March 03, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2021. Unless specified otherwise, all amounts in this press release ...